Good
Mostly Aligned
Patient Risk:
Low
Summary
Most immunization-related statements (e.g., avoiding live vaccines while on COSENTYX) align with the provided FDA label text. Several other specific claims about timing (e.g., 4 weeks before), vaccine components, and immune-seroconversion/adverse event mechanisms are not supported by the provided label excerpts and are therefore unsupported.
Category Scores
Accurate Statements
Avoid use of live vaccines in patients treated with COSENTYX.
Label 5.7 Immunizations: “COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.”
Unsupported Statements
Live vaccines such as MMR can pose added risk when used with Cosentyx.
The provided label excerpts do not mention MMR or specific live vaccines.
Current prescribing information advises against using live vaccines while taking Cosentyx.
Partially supported by the provided label excerpt (avoid use of live vaccines in patients treated with COSENTYX), but the wording is generalized; no additional context is provided beyond the excerpt.
Most patients should finish MMR vaccination at least four weeks before starting Cosentyx.
No 4-week timing guidance is present in the provided label excerpts.
If Cosentyx treatment is already underway, clinicians usually wait until therapy ends or pause it for four weeks around vaccination.
No timing guidance about pausing therapy for 4 weeks is present in the provided label excerpts.
MMR contains weakened live viruses.
The provided label excerpts do not describe MMR composition.
MMR requires an intact immune system to make antibodies without causing disease.
The provided label excerpts do not describe immunologic requirements for MMR.
Blocking interleukin-17A affects a pathway that helps fight intracellular pathogens and certain viruses.
The provided label excerpt under Mechanism of Action does not state this pathway detail.
Cosentyx impairs the immune response to live vaccines.
The label excerpt supports altered immune response to live vaccines, but the phrase “impairs the immune response” is a stronger/interpretive restatement not explicitly stated in the excerpt.
Cosentyx impairs the immune response to some inactivated vaccines as well.
The provided label excerpts do not address inactivated vaccine immune responses.
Clinical trials show lower seroconversion rates in patients treated with Cosentyx.
No seroconversion data are provided in the label excerpts.
Inactivated vaccines may still be used with Cosentyx but must be completed before therapy begins whenever possible.
The provided label excerpts only address live vaccines and completion of age-appropriate immunizations; they do not provide inactivated-vaccine timing language.
Potential adverse events include prolonged viral replication.
No such adverse event is mentioned in the provided label excerpts.
Potential adverse events include vaccine-strain infection.
No such adverse event is mentioned in the provided label excerpts.
Potential adverse events include failure to develop immunity.
No such adverse event/endpoint is mentioned in the provided label excerpts.
Data on specific rates of MMR adverse events under Cosentyx remain limited.
No MMR-specific adverse event rates are provided in the label excerpts.
No large-scale studies track MMR outcomes under Cosentyx.
No such study coverage statements are provided in the label excerpts.
Patients report questions about fever after vaccination.
The provided label excerpts do not include patient-reported vaccination reactions.
Patients report questions about rash after vaccination.
The provided label excerpts do not include patient-reported vaccination reactions.
Patients report questions about joint pain after vaccination.
The provided label excerpts do not include patient-reported vaccination reactions.
Cosentyx targets interleukin-17A.
The provided label excerpt supports IL-17A binding/inhibition (secukinumab binds IL-17A), but the claim is not explicitly tied to the excerpt’s name equivalence in the supplied text set for this evaluation context.
Cosentyx suppresses parts of the immune system.
The provided label excerpts do not use this wording; they discuss altered immune response to live vaccines and IL-17A involvement.
Cosentyx impairs the immune response to live vaccines.
The label says “may alter a patient's immune response to live vaccines”; the statement uses stronger phrasing not exactly reproduced.
Cosentyx impairs the immune response to some inactivated vaccines as well.
Not supported by provided label excerpts.
Contradictions
Important Omissions
The label advises completing all age-appropriate immunizations prior to initiating COSENTYX according to current immunization guidelines (not just avoiding live vaccines).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly supported, safety-relevant claim provided is to avoid live vaccines in patients treated with COSENTYX. Other detailed timing and adverse-event mechanism claims are unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple specific immunization-related details (e.g., MMR-specific risk, 4-week timing, inactivated vaccine effects, and vaccine-specific adverse events) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what the label excerpt states: consider completion of age-appropriate immunizations prior to COSENTYX and avoid use of live vaccines during COSENTYX treatment; remove or qualify unsupported specifics (MMR, exact timing intervals, inactivated vaccine immune effects, and specific adverse event mechanisms/rates).